Related Experiment Video

Updated: Jan 6, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.6K

Sirtuin modulators: a review of patents from 2020 to 2024

Emanuele Fabbrizi1,2, Francesco Fiorentino2,3, Antonello Mai1

  • 1Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, Italy.

Expert Opinion on Therapeutic Patents
|November 4, 2025
PubMed
Abstract

Insights

This review covers recent patents (2020-2024) on sirtuin modulators, crucial for aging, metabolism, and diseases like cancer. These sirtuin activators and inhibitors offer new therapeutic avenues.

Area of Science:

  • Biochemistry and Molecular Biology
  • Pharmacology and Drug Discovery
  • Genetics and Epigenetics

Background:

  • Sirtuins are key regulators of DNA repair, genome stability, and cellular signaling.
  • Sirtuin dysregulation is linked to pathologies including cancer, aging, and neurodegenerative diseases.
  • Targeted modulation of sirtuin isoforms is a critical area of therapeutic research.

Purpose of the Study:

  • To review patents on sirtuin modulators published between 2020 and 2024.
  • To provide an overview of the most relevant sirtuin modulators developed within this period.
  • To highlight the therapeutic potential of sirtuin activators and inhibitors.

Main Methods:

  • Systematic patent searches were conducted using PubMed, Google Patents, and Espacenet.
  • The review focused on patents published from 2020 to 2024.
  • Relevant patents concerning sirtuin modulators were identified and analyzed.

Main Results:

  • The review encompasses recent advancements in sirtuin modulator patents.
  • Key sirtuin activators and inhibitors with therapeutic potential are discussed.
  • Emerging technologies like PROTACs for isoform-specific degradation are highlighted.

Conclusions:

  • Sirtuin modulators are vital for addressing aging, metabolic disorders, cancer, and neurodegeneration.
  • Activators show promise for age-related diseases, while inhibitors are effective in oncology.
  • Continued progress in drug design and screening promises revolutionary treatments for complex diseases.
Keywords:
Epigeneticsagingcancerisoform selectivitymitochondrial enzymesneurodegenerationsirtuin modulatorssirtuins

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.6K
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K